Intrinsic Value of S&P & Nasdaq Contact Us

Standard BioTools Inc. LAB NASDAQ

NASDAQ Global Select • Healthcare • Medical - Devices • US • USD

SharesGrow Score
51/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$3.25
+232.5%

Standard BioTools Inc. (LAB) reported total assets of $567.75M and total liabilities of $143.46M for quarter ending 2025-12-31, resulting in total equity of $424.29M.

The company held $187.58M in cash and short-term investments. Total debt stood at $30.83M, with net debt of $-87.39M. The Debt-to-Equity (D/E) ratio was 0.07 (conservative).

Current ratio is 4.19, indicating strong short-term liquidity. Interest coverage is -2234.2x (weak).

Criteria supported by this page:

  • HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
  • MOAT (43/100) — Total assets $567.75M and equity $424.29M support the company's competitive scale
  • VALUE (100/100) — Debt-to-Equity 0.07 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 51/100 with 3/7 criteria passed.

SharesGrow 7-Criteria Score
51/100
SG Score
View full scorecard →
VALUE
100/100
Price-to-Earnings & upside
→ Valuation
FUTURE
73/100
Analyst consensus
→ Forecast
PAST
0/100
→ Income
~
HEALTH
67/100
Debt-to-Equity & liquidity
Proven by this page
MOAT
43/100
Proven by this page
GROWTH
65/100
→ Income
INCOME
10/100
→ Income
Standard BioTools Inc. Balance Sheet History
Metric Q4 FY2025 Q3 FY2025 Q2 FY2025 Q1 FY2025
Total Assets $567.75M$539.64M$556.97M$579.6M
Total Liabilities $143.46M$139.98M$132.43M$125M
Total Debt $30.83M$27.39M$28.62M$31.53M
Cash & Investments $187.58M$194.9M$237.09M$258.06M
Total Stockholders Equity $424.29M$399.66M$424.54M$454.6M
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message